US OptionsDetailed Quotes
AMRX240816C7500
- 0.55
- -0.20-26.67%
15min DelayClose Jul 26 15:58 ET
0.55High0.55Low
0.55Open0.75Pre Close10 Volume712 Open Interest7.50Strike Price550.00Turnover75.68%IV8.20%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.55Extrinsic Value100Contract SizeAmericanOptions Type0.5229Delta0.3064Gamma14.88Leverage Ratio-0.0140Theta0.0018Rho7.78Eff Leverage0.0068Vega
Amneal Pharmaceuticals Stock Discussion
Sign in to post a comment
$Amneal Pharmaceuticals(AMRX.US$ Amneal Pharmaceuticals Launches Focinvez, Ready-To-Use Injectable Anti-Nausea Agent For Chemotherapy; Second Injectable RTU Product Launched In 2024; Single-Dose Vial Free Of Polysorbate 80, No Reconstitution Required
1
1
$Amneal Pharmaceuticals(AMRX.US$ Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
$Amneal Pharmaceuticals(AMRX.US$ Amneal Launches PEMRYDI RTU, The First Ready-To-Use Version Of Important Oncology Injectable Medicine
Benzinga· 2 mins ago
Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma, does not require reconstitution, dilution, or refrigeration
Amneal plans to launch two to three branded oncology 505(b)(2) products per year going forward – this is the first of 2024
Benzinga· 2 mins ago
Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma, does not require reconstitution, dilution, or refrigeration
Amneal plans to launch two to three branded oncology 505(b)(2) products per year going forward – this is the first of 2024
$Amneal Pharmaceuticals(AMRX.US$ Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
1
$Amneal Pharmaceuticals(AMRX.US$
Wait for institutions to offer guidance before taking out gains !
Wait for institutions to offer guidance before taking out gains !
$Amneal Pharmaceuticals(AMRX.US$
DONT PaNICK
short sellers need to exit their position to cover, HOLD the GAIN(S)
DONT PaNICK
short sellers need to exit their position to cover, HOLD the GAIN(S)
$Amneal Pharmaceuticals(AMRX.US$ Amneal Pharmaceuticals (AMRX) said Tuesday it licensed its upcoming Parkinson's drug IPX203 to Zambon Biotech in the European Union, United Kingdom, and Switzerland.
Amneal's medicine is an oral formulation of the carbidopa-levodopa combo used to treat Parkinson's disease. IPX203 is currently under review in the US.
Zambon will seek regulatory approval and commercialize IPX203 in Europe, Amneal said.
Financia...
Amneal's medicine is an oral formulation of the carbidopa-levodopa combo used to treat Parkinson's disease. IPX203 is currently under review in the US.
Zambon will seek regulatory approval and commercialize IPX203 in Europe, Amneal said.
Financia...
1
The market has responded positively to Amneal Pharmaceuticals' growth and transition to profitability. Despite the long-term loss, the short-term total shareholder return suggests a potentially brighter future for the company.
$Amneal Pharmaceuticals(AMRX.US$ BRIDGEWATER, N.J., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today announced that it has provided a Complete Response resubmission to the U.S. Food and Drug Administration (FDA) for IPX203, a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson's disease (PD).
The original NDA for IPX203 resulted in a Complete Response Let...
The original NDA for IPX203 resulted in a Complete Response Let...
$Amneal Pharmaceuticals(AMRX.US$ Amneal Pharmaceuticals Announced Licensing Agreement To Have Exclusive Rights To Market And Distribute Ongentys (Opicapone) In U.S. Starting On December 18, 2023. Amneal Expects To Begin Distribution Of Ongentys In Early 2024![]()
No comment yet
Arrayfunction : It will be interesting to see what the ultimate market share of the drug will be. Did a quick read through the FDA label and compared it to Zofran's (the current "gold standard" as it were) label. Focinvez has some novel potential given it targets different brain receptors than Zofran and previous chemo anti-emetics.
That could help relieve some issues with drug-drug interactions current anti-emetics have (primarily serotonergic effects like SSRIs, serotonin modulators, etc). But it also means Focinvez has its own drug-drug interaction problems (most notably benzodiazepines and blood thinners).
I am not sure how often either issue would arise since I am not a doctor and haven't gone through chemo to know how often those other drug classes are prescribed together. So this may ultimately not have much of a financial impact if only a very small subset of chemo patients would benefit enough from adopting Focinvez to warrant the monumental increase in price compared to others on the market.